Diagnostics Investors

CRG is a premier healthcare-focused investment firm that has managed over $3 billion of institutional capital since inception and its senior investment professionals have led over 70 investments. The firm seeks to commit between $20 to $300 million in each investment across the healthcare spectrum, including: medical devices, biopharmaceuticals, tools & diagnostics, services and information technology. CRG provides growth capital in the form of long-term debt and equity to support innovative, commercial-stage healthcare companies that address large, unmet medical needs. The firm partners with public and private companies to provide flexible financing solutions and world-class support to achieve exceptional growth objectives with minimal dilution. CRG maintains offices in Boulder, New York and Houston. For additional information, please visit www.crglp.com.

Maryland Venture Fund is a private equity and venture capital firm specializing in direct and fund of fund investments. Within direct investments it makes seed, start-ups, early venture, mid venture and late venture investments. It also specializes in growth capital, bridge financing, industry consolidation, and recapitalization transactions. Within fund of fund investments it focuses on venture capital funds. The firm typically invests in companies operating in healthcare technology including healthcare equipment and supplies, diagnostics, medical testing, information technology, therapeutic devices, medical devices and instruments, software, platform, education technology, health, communications and information technology security, biotechnology, life sciences, and in companies engaged in the development of innovative and proprietary cyber security technology. It invests in companies based in Maryland. It invests between $0.1 million and $1 million per company. It seeks to invest in companies with revenues up to $1 million. It structures its investments in the form of equity and convertible debt. It seeks to invest in companies having fewer than 50 full-time employees, has been in active business not longer than five years, whose securities are not publicly traded on any exchange, and has been certified as a qualified Maryland cyber security company by the Maryland Department of Business and Economic Development. Maryland Venture Fund is based in Columbia, Maryland.

MTIP AG is a private equity firm specializing in later stage, emerging growth and growth capital investments. The firm seeks to invest in the healthcare, medical devices & technology, diagnostics, tech-enabled healthcare services and connected medical devices as well as digital health. The firm prefer to invest in European companies including Switzerland, UK and Israel. It prefers to invest up to €25 million ($29.89 million). It prefers to take a significant minority stake of more than 10% and a seat on the board of the investee companies. The firm prefer to exit in less than 5 years. The firm also considers follow-up investments. MTIP AG was founded in 2014 and is based in Basel, Switzerland with an additional office in Luxembourg.

OrbiMed Advisors LLC is a leading healthcare investment firm based in New York City, specializing in public and private investments across the healthcare and biotechnology sectors. Founded in 1998 by Samuel Isaly, Michael Sheffery, and Arvind Desai, OrbiMed has grown to become one of the world's largest dedicated healthcare investment firms, managing approximately $17 billion in assets as of March 2024. The firm's investment approach spans various stages of company development, from seed-stage startups to large multinational corporations, focusing on biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. OrbiMed's global team of over 130 professionals operates across multiple locations, including New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, and Herzliya, enabling the firm to provide tailored financing solutions and extensive resources to its portfolio companies. Notable achievements include raising over $4.3 billion across three private investment funds in October 2023, demonstrating strong investor confidence and the firm's commitment to driving innovation in the healthcare sector. Additionally, in May 2023, OrbiMed expanded its presence in Europe by opening a London office, further solidifying its position in the global healthcare investment landscape.

Accelmed is a private equity firm specializing in the healthcare technology sector. They focus on acquiring and growing commercial-stage HealthTech companies, with a particular emphasis on medical devices, tools and diagnostics, digital health, and tech-enabled services. Their approach involves working closely with management teams to enhance operations, update product portfolios, and revamp commercial organizations. Accelmed has a track record of successful investments and exits, demonstrating their commitment to building market-leading healthtech companies.

Immetric is a venture capital firm specializing in pre-seed, seed/startup, early stage and growth capital investments. The firm seeks to invest in emerging technologies and deep tech including medtech, diagnostics, consumer electronics, robotics, automation, Internet of Things, transport, renewables, and clean tech. The firm seeks to invest in Nordics, United Kingdom and Western Europe. Immetric is based in Malmö, Sweden.

RADFORSK, formerly known as The Norwegian Radium Hospital Research Foundation, is a venture capital firm specializing in investments in pre-seed, start-up, early-stage, incubation, and project development. The firm also provides advisory services. It seeks to invest in biotechnology and cancer focused companies. It also prefers to invest in oncology, novel therapeutics and diagnostics, with a key focus on immune-oncology. The firm typically invests in companies based in Europe with a specific focus on Norway. It prefers to invest in companies based on the continuing flow of innovations from leading Nordic research institutions. The firm also seeks co-investment opportunities. RADFORSK was founded in 1986 and is based in Oslo, Norway with an additional office in Lysaker, Norway.

Arkray 4U is a venture capital arm of ARKRAY, Inc. specializing in startups. It seeks to invest in the healthcare and related sectors, like digital healthcare, medtech, biotech, AI, IoT medical devices, cloud pharmacies, medical diagnostics, personal wellness & self-care, pet-tech, medical and functional foodtech. The firm focuses on Japan, Southeast Asia, India and Israel. It doesn’t have a minimum cheque size but it may invest up to JPY 300 million ($2.61 million) per company. Arkray 4U is based in Singapore.

CBC Group is a private equity and venture capital firm specializing in incubation, early stage, seed startup, growth capital, late stage, emerging growth, mature, and buyout investments. The fund typically invests in the healthcare sector with a focus on life sciences, med-tech, bio-technology, pharmaceuticals,IVD, mobile health care, medicine, diagnostics, medical services, and medical devices with a focus on investing in the treatment of Hepatitis B and lung cancer. The firm prefers to seek controlling acquisition opportunities and minority investment strategies in pharmaceutical and biotechnology, medical technology and medical services. It seeks to invest globally specifically in Asia-Pacific, especially China, the United States, and Israel. CBC Group was founded in 2014 and is based in Singapore, with additional offices in Asia and United States.

Sciety AB is a Venture capital firm specializing in seed/startup and early venture. It seeks to invest in Life Sciences companies in Sweden. The firm makes Balance Sheet Investments. It prefers to invest in life science, biotechnology, medical technology, pharmacology, diagnostics, healthcare and health tech sectors. It seeks to invests in companies based in Nordic region. Sciety AB is based in Stockholm, Sweden with an additional office in Gothenburg, Sweden.

Abingworth is a transatlantic life sciences investment firm that partners with entrepreneurs to turn breakthrough science into medicine. Investing across all stages from seed to public companies, they focus on biopharma, therapeutics, medical devices, and diagnostics with offices in London, New York, and San Francisco.

BioAdvance is a venture capital firm specializing in seed, start up, early stage, series A and emerging growth investments. The firm seeks to invest in life sciences, therapeutic agents, diagnostics, health information technology, medical devices, digital health, research tools, and platform technologies focused on human health. It prefers to invest in Mid-Atlantic companies mainly based in the Southeastern region of Pennsylvania, New York, New Jersey, Delaware, Maryland, Virginia, West Virginia, and Washington, D.C. in the United States. The firm initial investment size typically ranges between $0.5 million to $1.5 million and can commit up to $5 million over the lifetime of companies with the potential to significantly improve human health. It consider leading rounds between $0.5 million and $5 million, BioAdvance was founded in 2003 and is based in Conshohocken, Pennsylvania.

Swan Venture Fund, Llc is venture capital firm specializing in pre-seed, seed stage and early-stage companies. The firm typically invests in B2B software, market-accelerating technologies, capital-efficient hard-science, diagnostics & healthIT, medical devices, scalable IoT and scalable hardware The firm primarily invests in Pacific Northwest, Seattle, Portland, Denver and Vancouver. Swan Venture Fund, Llc is based in Kirkland, Washington.

GPB Capital Holdings, LLC is no longer investing. It is a private equity firm specializing in acquisition of middle market, and buyout companies. The firm seeks to invest in the automotive retail, managed information technology services, and life sciences sectors. Within the life sciences sector, it typically invests in revenue stage companies in niche areas including approved drugs, orphan drugs, generic drugs, devices, diagnostics, and tools. It also invests in, Technology Enabled Services, Debt Strategies, Special Situations, Waste Management, Real Estate, Alternative Investments, Energy, Business Services, Communications, Manufacturing, Retail, healthcare equipment’s, medical instruments, and Healthcare. Within waste management it invests in solid Waste Management, recycling sectors. Within Debt strategies it prefers to invest in secured loans to small and medium-sized North American businesses. In debt strategies, it invest between $5 million to $50 million. The firm typically have a 36-month duration. It considers investments in companies based in the United States, and North America. The firm seeks to invest in companies that intend to go public. It seeks to invest in companies where the management teams provide first risk capital or provide personal guarantees. The firm prefers to invest in equity secured by a first lien on the assets of the portfolio company. The firm seeks to hold a majority of the seats on the portfolio company’s Board of Directors. GPB Capital Holdings, LLC was founded in 2013 and is based in Greenwich, Connecticut with additional office in New York, New York, Palm Beach Gardens, Florida.

NMT Capital is a venture capital firm specializing in early venture, mid venture, and late venture investments. The firm primarily invests in information technology, medical technology, and life science companies with a focus on medical devices, diagnostics, advanced materials, equiptment, biotechnology, specialty pharmaceutical, life sciences, and drug discovery tools. It considers investments in the United States, Europe, the Middle East and Asia, especially in companies seeking either to expand outside their region or to attract companies into their region. The firm prefers to be the lead investor in its portfolio companies. NMT Capital was formerly known as Nexus Medical Partners. NMT Capital was founded in 2004 and is based in Norwell, Massachusetts with additional offices in Greenville, South Carolina and Luxembourg, Luxembourg.

ORI Capital is a venture capital firm specializing in seed, early stage to Series B, and late stage investments. It seeks to invests in innovative companies with disruptive technologies in the healthcare industry. The firm invests in the field of therapeutics, drug delivery, and diagnostics that address diseases with high mortality rates such as cancers, neurodegenerative and metabolic diseases, as well as rare diseases caused by genetic mutation. It seeks to invest globally. The firm prefers to exit its investment through M&A. ORI Capital was founded in 2015 and is based in Wanchai, Hong Kong.

TPG Biotech is the life sciences venture capital platform of TPG, a leading global alternative asset manager. Established in 2002, TPG Biotech focuses on investing in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, and industrial applications of biotechnology. The firm leverages TPG's extensive resources and expertise to support companies developing disruptive science, technologies, and business models aimed at improving patient outcomes in areas with significant unmet medical needs. TPG Biotech's investment strategy is thematic, concentrating on sectors such as oncology, autoimmune and inflammatory diseases, cardiometabolic diseases, ophthalmology, rare diseases, as well as commercial-stage medical devices and tech-enabled services. The team brings deep scientific, clinical, and operational expertise to its investments, partnering with companies from early-stage development through clinical trials to commercialization. This approach is built upon TPG's market-leading healthcare franchise, which has invested over $30 billion across the global healthcare ecosystem since 2003.

Altaris, LLC is a private equity firm specializing in corporate carve outs and partnerships, acquisitions, debt financing, private equity / buyouts fund, venture capital fund, recapitalization, divestitures, strategic co-ownership arrangements, leverage buyouts, PIPES, middle market, industry consolidation and growth capital investments. It prefers to invest in pharmaceuticals, therapeutics, contract development and manufacturing, drug delivery technologies, medical devices, outsourced design and manufacturing, supply chain, minimally invasive technologies, life sciences and diagnostics, bioprocessing, advanced imaging & precision medicine, R&D efficiency, healthcare services, technology-enabled services, digitization of processes, and preventative care and wellness sectors. The firm prefers to invests in companies in the United States, Canada, North America and Western Europe. It prefers to invest in equity investment between $50 million and $500 million. It makes control, majority, and significant minority investments. Altaris, LLC was founded in 2003 and is based in New York, New York.

ArchiMed SAS is a private equity and venture capital firm specializing investing in small and middle market, growth buyouts, acquisitions, small-cap and mid-cap companies. The firm seeks to invest in healthcare industries with focus on biopharmaceutical products & services, life science tools, biologic services, medical devices & technologies, diagnostics, healthcare IT and consumer health. In Biopharma firm prefers to invest in small and large molecules, APIs, generic, primary and specialty pharma, pharma delivery, veterinary, outsourcing services such as bioanalytical, drug discovery or formulation services, Consumer Health, In Vitro Diagnostics, CRO, CDMO, CLO or specialized consulting, in Healthcare IT firm prefers to invest in clinical or non-clinical solutions for care providers, care payer solutions, biopharma-related software, outsourcing services. In care provider firm prefers to invest in homecare, specialized care delivery, outsourcing services, in Medtech firm provider, the firm prefers to invest in implants, equipment, consumables, services, outsourcing in field such as cardiovascular, dental, drug delivery, infection control, neuro, ophtalmo, orthopaedics, general surgery, wound care, veterinary, in public safety firm prefers to invest in biocontrol, food safety, environmental and healthcare-related TIC, health at work, in Diagnostics it prefers to invest in including In Vitro (IVD) and Imaging, in Life Sciences the firm prefers to invest in including tools, equipment, consumables and services, whether for bioprocessing, research, in consumer health it prefers to invest in cosmetics, health supplements, aesthetics, wellness, selfcare and physio. It prefers to invest in Europe, France, Switzerland, North America, APAC and LATAM region. It prefers to invest between €5 million ($5.36 million) and €1,000 million ($1,100 million) in the companies with sales value between $6.22 million and $124.33 million. It prefers to take majority and minority stake in the companies. ArchiMed SAS was founded in 2014 and is based in Lyon, France with additional offices in Paris, France; New York, New York; Singapore, Singapore and Tokyo, Japan.

ATEM Capital is a venture capital firm specializing in early-stage, late stage and growth capital investments. The firm seeks to invest in healthcare, biotech and life sciences sector - 70% in the biotechnology / pharmaceuticals, which includes 20% early stage assets and 50% late stage assets and the rest 30% investments in de-risked medical devices and diagnostics. It focuses its investments in life-saving, life changing and pregnancy related technologies which includes oncology, cardio-vascular, anti-infectives, CNS/pain, and women's health. The firm considers investing in the United States and Western Europe including Vancouver, San Francisco, San Diego, Chicago, Montreal, Boston, New York, London, Amsterdam, Paris, Basel, and Berlin. It seeks to invest in companies listed on major stock exchanges with market capitalization under $300 million. The firm also makes direct co-investments. ATEM Capital is based in New York, New York.

AV8 Ventures is an early-stage venture capital firm founded in 2018, with offices in Palo Alto, California, and London, United Kingdom. The firm specializes in investing in seed and Series A startups across sectors such as healthcare, enterprise technology, financial services, and deep-tech. Backed by Allianz SE, AV8 Ventures focuses on partnering with visionary entrepreneurs to build category-defining companies. The firm's team comprises experienced professionals with backgrounds in launching products, building teams, and scaling revenue, offering hands-on support to portfolio companies. Their network includes experts in health, machine learning, enterprise technology, mobility, robotics, hard sciences, and biology, providing comprehensive assistance to startups. Notable investments include Alpha Medical, Delfi Diagnostics, Eclypsium, and Embrace.io.

Capital-E NV is a private equity and venture capital firm specializing in seed/start-ups and early stage investments. The firm seeks to invest in micro and nano electronics, nanotechnology, and advanced materials with a focus on image sensors, machine learning, artificial intelligence, industry 4.0, medical and diagnostics, semicon processing and metrology, communications and networking, green energy, and consumer electronics and multimedia. Within communication, the firm focuses on analogue and mixed signal chip solutions, RF technologies and components for communication and sensor networks, solutions with significantly higher integration/performance/power efficiency benchmarks for existing and emerging markets and also seeks to invest in novel concepts and components as well as system level solutions for both wired as well as wireless applications and defensible proprietary technology and innovative business models to compete. Within semicon processing and metrology, it focuses on equipment and materials technologies for the fabrication, process control or inspection of (un) patterned wafers compatible with standard CMOS integrated circuits aiming for unparalleled device performance and yield. Within consumer electronics and multimedia, it seeks to invest in large area of applications, ranging from subsystems, devices and networks, facilitating new functionality, analogue and mixed signal chip technologies for ambient, slimmer, less power hungry, better performing electronic devices. Within multimedia, it prefers to invest in innovative technology approaches in chips, modules, and embedded software / signal processing to deliver the next generation of multimedia applications. Within green energy, it invests in novel tools, materials, systems, processes and device structures for power generation and control, energy scavenging and storage with emphasis on power density, efficiency and lower cost; functional coatings or conductive polymers enabling renewable energies, tiny-tech filter or purification materials, structural composites, sustainable catalysis or simply the recovery of high value materials; and future mobility solutions (components) with electric vehicles as an integral part of intelligent power networks, smart grids, and the corresponding infrastructure. It also invests in processing, test and metrology equipment, sensors, memories and intra/interchip optical communication. The firm primarily focuses on Western Europe with a specific focus on the Benelux, Netherlands, Flanders, and Luxembourg. It also pursues co-investments in the United Kingdom, Benelux, Ireland, France, and Germany. It seeks to invest between €0.25 million ($0.32 million) to €1 million ($1.29 million) scaling to € 7.5 million ($9.81 million) per company over multiple rounds. The firm seeks to be an active board member on its portfolio companies. It prefers to lead deals and co-invest in subsequent rounds of financing. Capital-E NV was founded in January 2006 and is based in Antwerp, Belgium.

LYFE Capital is a Shanghai-based venture capital firm founded in 2015, specializing in early-stage investments within the healthcare sector, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, and digital health. The firm focuses on companies with established products seeking capital to accelerate growth, particularly in Greater China. Beyond financial support, LYFE Capital offers market planning, talent acquisition, global expansion, and partnership assistance to its portfolio companies. As of 2025, LYFE Capital has made 146 investments and achieved 22 successful exits.

We invest in Digital Health, Healthtechs, Medical Devices, Medtech, Biotech, Techbio, Diagnostics and other healthcare startups. They need to either reduce healthcare costs or improve clinical outcomes (ideally both), and have advanced clinical trials (in case it is needed).

BC Mgmt, Inc. is a venture capital firm specializing in startup/seed, early stage and series A investment. The firm does not invest advertising, marketing, music, movies, gaming and traditional food, beverage, restaurant, retail and real estate. The firm primarily seeks to invest in agriculture & food, transport & auto, medical diagnostics & pharma, robotics & semiconductors, financial and consumer products. The firm typically invests in the United States, Canada, Europe and Asia/Pacific. The firm don’t take large stakes and board seats. BC Mgmt, Inc. was founded in 2014 and is based in San Mateo, California.